全球粒子治疗市场规模（按类型、产品类型、癌症类型、区域范围和预测）

粒子治疗市场规模及预测

2024 年粒子束治疗市场规模价值为 12.3694 亿美元，预计到 2032 年将达到 25.7345 亿美元，2026 年至 2032 年的复合年增长率为 9.59%。

粒子治疗是一种体外放射治疗，利用质子、中子和较重离子（例如碳）等带电粒子来治疗癌症。其最大的优点在于布拉格峰，即粒子将大部分能量沉积在特定深度时产生的布拉格峰，因此能够精确地瞄准肿瘤，同时限制对邻近健康组织的损害。这种精确性使得粒子治疗对常规光子治疗无效的癌症尤其有效。

此外，粒子治疗也用于治疗多种疾病，包括脑肿瘤、前列腺癌和儿童恶性肿瘤，与标准放射技术相比，其副作用更少，患者的生活品质更高。

全球粒子治疗市场动态

影响粒子治疗市场的关键市场动态是：

关键市场驱动因素

癌症发生率上升：全球癌症发生率的上升是粒子束治疗市场的主要驱动力。根据世界卫生组织 (WHO) 的数据，癌症是全球首要死因，预计到 2020 年将导致约 1,000 万人死亡。根据国际癌症研究机构 (IARC) 的数据，2020 年全球新增癌症病例 1,930 万例，预计到 2040 年将增至 2,840 万例。日益加重的癌症负担催生了对粒子束治疗等创新治疗方法的需求。粒子束治疗是加护治疗副作用可能比传统放射疗法更少。

粒子治疗技术进步：粒子治疗系统的持续技术进步正在拓展其应用范围，并刺激市场扩张。根据美国国家癌症研究所 (NCI) 的数据，2021 年美国已有 37 个粒子治疗中心运作，另有多个正在建造或规划中。根据粒子治疗合作组织 (PTCOG) 的统计数据，截至 2021 年，全球整体已有 103 个粒子治疗设施运作，另有 41 个正在建设中。设施数量的快速增长反映了粒子治疗系统的广泛应用和技术日益成熟。

医疗支出不断增长：医疗支出不断增长，尤其是在已开发国家，正在加速粒子束疗法等创新癌症治疗方法的普及。根据经济合作暨发展组织(OECD) 的数据，2019 年 OECD 国家的医疗支出成长快于经济成长，平均占 GDP 的 8.8%。根据美国医疗保险和医疗补助服务中心 (CMS) 的数据，到 2020 年，全国医疗支出将增加 9.7%，达到 4.1 兆美元，人均医疗支出将达到 12,530 美元。医疗支出的不断增长促使人们投资于粒子束疗法等最先进治疗，从而推动市场成长。

主要问题

营运成本高：建立和运作粒子治疗中心需要对迴旋加速器和同步加速器等先进技术进行大量投资，这对许多医疗机构来说成本高昂。这一经济障碍减少了可用的治疗中心数量，尤其是在新兴国家，限制了患者获得这种新型医疗手段的机会，并阻碍了整体市场的成长。

医护人员认知度有限：儘管粒子疗法益处良多，但许多肿瘤科医师和医护人员仍未意识到其相较于传统疗法的优势。这种认知差距导致粒子治疗替代方案利用不足，患者未被转介至更先进的治疗方案。加强医护人员的教育和培训，对于提高粒子治疗的采用率并改善癌症治疗的患者预后至关重要。

主要趋势

癌症发生率不断上升：预计到 2022 年，全球新患者将达到 2,000 万，对粒子束治疗等先进治疗方法的需求也日益增长。这一趋势促使医疗保健专业人员使用能够有效治疗恶性肿瘤的新治疗方法，同时减少对健康组织的损害，改善患者的预后和生活品质。

加大医疗基础设施投资：包括日本和中国在内的亚太国家正在大力投资建造更多的粒子治疗中心。此类基础设施的扩建对于满足日益增长的晚期癌症治疗需求至关重要，因为这些目标人口庞大，且存在大量未满足的需求。粒子治疗可近性的改善有望加速这些地区的粒子治疗普及。

目录

第一章全球粒子治疗市场介绍

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章全球粒子治疗市场展望

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

第五章全球粒子治疗市场（按类型）

• 概述
• 重离子束
• 质子治疗

第六章全球粒子治疗市场（按产品）

• 概述
• 迴旋加速器
• 同步加速器
• 同步迴旋加速器

第七章全球粒子治疗市场（依癌症类型）

• 概述
• 儿童癌症
• 摄护腺癌
• 肺癌
• 乳癌

第八章全球粒子治疗市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 其他的
  • 拉丁美洲
  • 中东和非洲

第九章全球粒子治疗市场的竞争格局

• 概述
• 各公司市场排名
• 重点发展策略

第十章 公司简介

• Accuray Incorporated
• Brainlab
• Elekta AB
• Xstrahl
• Danfysik A/S
• Hitachi Ltd
• Mevion Medical Systems
• IBA Worldwide
• Panacea
• Shinva Medical Instrument Co. Ltd.

第十一章 附录

• 相关调查

Particle Therapy Market Size And Forecast

Particle Therapy Market size was valued at USD 1236.94 Million in 2024 and is projected to reach USD 2573.45 Million by 2032, growing at a CAGR of 9.59% from 2026 to 2032.

Particle therapy is a type of external beam radiotherapy that uses charged particles, such as protons, neutrons, or heavier ions (such as carbon), to treat cancer. Its greatest advantage is the Bragg peak, which occurs when particles deposit the majority of their energy at a given depth, allowing for accurate tumor targeting while limiting harm to adjacent healthy tissues. This precision makes particle therapy especially useful for cancers that are resistant to traditional photon-based therapies.

Furthermore, particle therapy is used to treat a variety of diseases, including brain tumors, prostate cancer, and pediatric malignancies, with fewer side effects and a higher quality of life for patients than standard radiation techniques.

Global Particle Therapy Market Dynamics

The key market dynamics that are shaping the Particle Therapy Market include:

Key Market Drivers

Rising Cancer Incidence: The growing prevalence of cancer worldwide is a primary driver of the Particle Therapy Market. According to the World Health Organization (WHO), cancer is the biggest cause of death worldwide, accounting for approximately 10 million deaths in 2020. According to the International Agency for Research on Cancer (IARC), there were 19.3 million new cancer cases worldwide in 2020, with the number expected to climb to 28.4 million by 2040. The expanding cancer burden is generating demand for innovative treatment methods such as particle therapy, which provides focused treatment with possibly fewer side effects than conventional radiotherapy.

Technological Advancements in Particle Therapy: Continuous technological advancements in particle treatment systems are broadening their applications and fueling market expansion. According to the National Cancer Institute (NCI), 37 particle therapy centers were in operation in the United States in 2021, with several more under construction or in the planned stages. According to the Particle Therapy Co-Operative Group (PTCOG) statistics, there were 103 particle therapy facilities in operation globally as of 2021, with an additional 41 under construction. This rapid growth of facilities reflects the increasing adoption and technological maturity of particle therapy systems.

Increasing Healthcare Expenditure: Rising healthcare spending, particularly in industrialized countries, is accelerating the adoption of innovative cancer treatment methods such as particle therapy. According to the Organization for Economic Cooperation and Development (OECD), health spending in OECD countries increased faster than economic growth in 2019, accounting for 8.8% of GDP on average. According to the Centers for Medicare and Medicaid Services (CMS), national health spending increased by 9.7% to USD 4.1 Trillion in 2020, or $12,530 per person. This increased healthcare spending allows for investments in cutting-edge treatments such as particle therapy, which drives market growth.

Key Challenges:

High Operational Costs: Establishing and operating particle therapy centers necessitates significant investment in advanced technology, such as cyclotrons and synchrotrons, which are prohibitively expensive for many healthcare facilities. This financial barrier reduces the number of available treatment centers, particularly in developing countries, limiting patient access to this new medicine and impeding overall market growth.

Limited Awareness among Healthcare Providers: Despite the benefits of particle therapy, many oncologists and healthcare professionals remain unaware of its advantages over traditional treatments. This awareness gap results in the underutilization of particle therapy alternatives, as patients are not recommended for advanced therapies. Increased education and training for healthcare practitioners are critical to increasing adoption rates and improving patient outcomes in cancer treatment.

Key Trends:

Growing Prevalence of Cancer: The need for advanced treatment modalities like particle therapy is growing as the number of new cases of cancer is expected to reach 20 million worldwide in 2022. This trend is encouraging healthcare practitioners to use novel therapies that reduce damage to healthy tissues while efficiently treating malignancies, thereby improving patient outcomes and quality of life.

Increased Investment in Healthcare Infrastructure: Countries in Asia Pacific, including Japan and China, are making significant investments to develop more particle therapy centers. This infrastructure expansion is critical for supporting the growing demand for advanced cancer treatments, which is driven by a large target population and significant unmet clinical needs. Improved access to particle therapy is expected to accelerate its adoption in these regions.

Global Particle Therapy Market Regional Analysis

Here is a more detailed regional analysis of the Particle Therapy Market:

North America:

According to Verified Market Research, North America is estimated to dominate the market during the forecast period. North America, particularly the United States, has a high cancer burden, which drives the desire for sophisticated treatment options such as particle therapy. According to the American Cancer Society's Cancer Facts & Figures 2023, the United States is expected to see 1,958,310 new cancer cases and 609,820 cancer deaths in 2023. The National Cancer Institute estimates that 39.5% of men and women will be diagnosed with cancer at some point in their lives. This high incidence rate is a major driving force behind the region's adoption of novel cancer treatments such as particle therapy.

Furthermore, North America has a robust healthcare research and development ecosystem, which fosters advances in cancer treatment technology. The National Cancer Institute (NCI) states that it got $6.9 billion for cancer research in fiscal year 2022, with a significant portion of that going toward discovering and refining cancer treatment modalities. Also, the Particle Therapy Co-Operative Group (PTCOG) said that as of 2021, 37 particle treatment facilities were in operation in North America, with several more under construction or in the planning phases. This concentration of research funds and infrastructure demonstrates the region's commitment to developing particle therapy methods and treatments.

Asia Pacific:

The Asia Pacific region is estimated to exhibit the highest growth within the market during the forecast period. The Asia-Pacific region has experienced a huge increase in cancer diagnoses, fueling demand for innovative treatment alternatives such as particle therapy. According to the World Health Organization's International Agency for Research on Cancer (IARC), the Asia-Pacific region accounted for 49.3% of all new cancer cases worldwide in 2020. According to GLOBOCAN 2020 data, there were approximately 9.5 million new cancer cases in Asia in 2020, with the number expected to rise to 14.7 million by 2040. This significant and growing cancer burden is a crucial factor in the region's adoption of novel cancer treatments like particle therapy.

Furthermore, many Asian countries are aggressively promoting the research and application of innovative medical technologies, such as particle therapy. For example, Japan, a leader in particle therapy in Asia, has received major government backing for this technique. According to the Particle Therapy Co-Operative Group (PTCOG), Japan has the most particle therapy facilities in Asia, with 20 operational as of 2021. The Japanese government has designated particle treatment as an "advanced medical technology" and is providing financial assistance for its development and deployment. Similarly, countries such as China and South Korea are rapidly growing their particle therapy capabilities, with official support.

Global Particle Therapy Market: Segmentation Analysis

The Particle Therapy Market is segmented on the basis of Type, Product, and Cancer Type.

Particle Therapy Market, By Type

• Proton Therapy
• Heavy Ion Therapy

Based on Type, the market is segmented into Proton Therapy and Heavy Ion Therapy. The proton therapy segment is estimated to dominate the Particle Therapy Market due to proton therapy's precision targeting capabilities, which enable the effective treatment of many malignancies while minimizing damage to adjacent healthy tissues. Its improved dose distribution and low long-term adverse effects make it especially appealing for pediatric cases and complicated cancers, resulting in widespread acceptance among healthcare providers and patients. As technology advances and treatment delivery improves, proton therapy's position as the top choice in particle therapy is projected to strengthen further.

Particle Therapy Market, By Product

• Cyclotrons
• Synchrotrons
• Synchrocyclotrons

Based on Product, the Particle Therapy Market is segmented into Cyclotrons, Synchrotrons, and Synchrocyclotrons. The cyclotrons segment is estimated to dominate the market over the forecast period. Cyclotrons are critical components of proton therapy systems, producing and accelerating protons to provide targeted radiation to malignancies. Their broad use is driven by their efficacy in treating a variety of malignancies, including pediatric instances and complicated tumors. As healthcare facilities spend more on innovative cancer treatment technologies, the need for cyclotrons is likely to increase, strengthening their market dominance.

Particle Therapy Market, By Cancer Type

• Pediatric Cancer
• Prostate Cancer
• Lung Cancer
• Breast Cancer
• Others

Based on Cancer Type, the market is divided into Pediatric Cancer, Prostate Cancer, Lung Cancer, Breast Cancer, and Others. The pediatric cancer segment is estimated to dominate the global market due to a growing knowledge of children's unique therapeutic demands, which are particularly vulnerable to radiation. Particle therapy's precision reduces damage to surrounding healthy tissues, making it an excellent choice for treating pediatric cancers. As knowledge of the efficacy and safety of particle therapy in younger patients grows, this segment is projected to maintain its market leadership.

Key Players

• The "Particle Therapy Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Accuray Incorporated, Brainlab, Elekta AB, xstrahl, Danfysik A/S, Hitachi Ltd., Mevion Medical Systems, IBA Worldwide, Panacea, and Shinva Medical Instrument Co. Ltd.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Particle Therapy Market Recent Developments
• In September 2023, Siemens Healthineers AG showcased breakthrough technology at the American Society for Radiation Oncology (ASTRO) 2023 annual meeting in California, demonstrating their dedication to innovation and improved results.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PARTICLE THERAPY MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL PARTICLE THERAPY MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL PARTICLE THERAPY MARKET, BY TYPE

• 5.1 Overview
• 5.2 Heavy Ion
• 5.3 Proton Therapy

6 GLOBAL PARTICLE THERAPY MARKET, BY PRODUCT

• 6.1 Overview
• 6.2 Cyclotrons
• 6.3 Synchrotrons
• 6.4 Synchrocyclotrons

7 GLOBAL PARTICLE THERAPY MARKET, BY CANCER TYPE

• 7.1 Overview
• 7.2 Pediatric Cancer
• 7.3 Prostate Cancer
• 7.4 Lung Cancer
• 7.5 Breast Cancer

8 GLOBAL PARTICLE THERAPY MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL PARTICLE THERAPY MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Accuray Incorporated
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Brainlab
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Elekta AB
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Xstrahl
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Danfysik A/S
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Hitachi Ltd
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Mevion Medical Systems
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 IBA Worldwide
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Panacea
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Shinva Medical Instrument Co. Ltd.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research